Surveillance analysis of adverse event following immunization for meningococcal vaccines in Nanyang city,Henan province,2013-2022
Objective To analysis characteristics of adverse event following immunization(AEFI)for group A meningococcal polysaccharide vaccine in(MPV-A),group A and C meningococcal polysaccharide vaccine(MPV-AC),group A and C meningococcal polysaccharide conjugate vaccine(MPCV-AC),group ACYW135 meningococcal polysaccharide vaccine(MPV-ACYW135),and group A and C meningococcal conjugate Haemophilus influenza type b conjugate combination vaccine(MPCV-AC-Hib)in Nanyang city,and preliminarily evaluate vaccine safety.Methods AEFI cases and vaccination doses of the five meningococcal vaccines(MPV-A,MPV-AC,MPCV-AC,MPV-ACYW135,and MPCV-AC-Hib)administered and reported from Nanyang between 2013-2022 were collected through China AEFI Surveillance and Management System and Henan Information Management Systems for Immunization.Analysis was performed using the description epidemiology.Results In total,1 979 AEFI cases were reported from Nanyang between 2013-2022,and the average annual reported incidence was 40.22/105 doses.The reported incidence of AEFI for the 5 vaccines was between 20.80/105-60.83/105 doses with a significant difference(x2=293.203,P＜0.05).There were 1 966 general reactions reported with the incidence rate of 39.96/105.Abnormal reactions occurred in 10 cases with the incidence of 0.20/105 doses.The main clinical symptoms of the general reactions were fever(1 600 cases,81.38％),with the incidence of 32.52/105 doses;abnormal reactions were mainly diagnosed as allergic rash(6 cases,60.00％)with the incidence of 0.12/105 doses.Of the AEFI cases,1 977(99.90％)were recovered.Conclusions From 2013-2022,the reported incidence of AEFI for meningococcal vaccines used in Nanyang city was low;most of them were general reactions,having good prognosis;and the vaccines had good safety.
Meningococcus vaccineAdverse events following immunizationSafety
NETL
NSTL
万方数据
